Welcome to our dedicated page for Aytu Biopharma SEC filings (Ticker: AYTU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aytu BioPharma, Inc. (AYTU) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Aytu is a Nasdaq Capital Market–listed pharmaceutical company focused on complex central nervous system diseases, including major depressive disorder (MDD) and attention deficit-hyperactivity disorder (ADHD). Its filings offer detailed insight into financial performance, capital structure, governance and key product developments.
Through current reports on Form 8-K, Aytu reports material events such as fiscal quarter and full-year operational and financial results, conference call details and significant financing arrangements. For example, 8-K filings describe quarterly net revenue by portfolio, adjusted EBITDA, cash balances and updates on the commercial launch of EXXUA (gepirone) extended-release tablets, as well as the terms of amendments to its loan and security agreements.
Aytu’s definitive proxy statements (DEF 14A) outline matters submitted to stockholders, including director elections, ratification of the independent registered public accounting firm and advisory votes on executive compensation. These documents also explain voting procedures, quorum requirements and distinctions between stockholders of record and beneficial owners.
On Stock Titan, Aytu’s 10-K annual reports and 10-Q quarterly reports (when available) can be reviewed alongside 8-K, DEF 14A and other forms, with AI-powered summaries that highlight key points such as segment performance, CNS and ADHD portfolio contributions and risk disclosures. Users can also track Form 4 insider transaction filings to monitor equity awards and share transactions by officers and directors. Real-time updates from EDGAR and AI-generated explanations help investors navigate lengthy documents, understand how EXXUA and other products are reflected in Aytu’s financials and governance, and quickly locate the information most relevant to their analysis.
Aytu BioPharma, Inc. shareholder Laurence W. Lytton filed an amended Schedule 13G reporting his beneficial ownership in the company’s common stock. Lytton reports beneficially owning 1,071,351 shares and warrants, representing 9.99% of the common stock outstanding.
The Lytton-Kambara Foundation reports beneficial ownership of 895,528 shares and warrants, representing 8.8% of the class. Both positions include common shares and warrants subject to a 9.99% beneficial ownership limitation, with percentages calculated using 10,188,208 shares outstanding as of November 1, 2025. The filer certifies the holdings are not for the purpose of changing or influencing control.
AYTU BioPharma, Inc. received an amended Schedule 13G showing that Investment Company, Inc., a Delaware corporation, reports beneficial ownership of 619,574 shares of AYTU common stock, equal to 5.8% of the class as of the event date 12/31/2025.
The shares are held by Special Situations Private Equity Fund, L.P., for which Investment Company, Inc. serves as investment adviser with sole voting and dispositive power. The filer certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of AYTU.
Aytu BioPharma reported a weaker quarter as it reshapes around central nervous system medicines. For the three months ended December 31, 2025, net revenue from continuing operations was $15.2 million, down from $16.2 million a year earlier, with six‑month revenue at $29.1 million versus $32.8 million.
The company posted a net loss of $10.6 million for the quarter, compared with net income of $0.8 million in the prior‑year period. Results were heavily affected by an $8.2 million loss on derivative warrant liabilities, while loss from operations widened modestly. Six‑month net loss was $8.6 million, versus income of $2.3 million a year ago.
Cash and cash equivalents were $30.0 million, with positive operating cash flow of $3.1 million for the six months. Debt consisted of a $12.1 million term loan and $9.1 million drawn on a revolving credit facility, alongside $27.3 million of derivative warrant liabilities. The quarter also included the initial EXXUA antidepressant launch, generating $0.2 million of revenue, while the ADHD and pediatric portfolios declined.
Aytu BioPharma, Inc. announced that it issued a press release detailing its fiscal 2026 second quarter operational and financial results. The company also scheduled a public conference call and live audio webcast on February 3, 2026 at 4:30 p.m. Eastern time to discuss these results and answer questions.
The call is accessible by webcast and telephone, with replay options available on Aytu’s website and via telephone, subject to the company’s discretion. The press release containing the results is furnished as an exhibit, but is not treated as filed for liability purposes under federal securities laws.
Aytu BioPharma, Inc. filed a current report describing investor communications held on January 20, 2026. The company issued a press release titled “Aytu BioPharma Recaps Investor Day Held on January 20, 2026,” which is furnished as an exhibit. Aytu also posted an investor presentation on its website used in an investor meeting that same day.
The presentation, attached as another exhibit, includes information about the EXXUA™ (gepirone) extended-release tablets opportunity, giving investors additional detail on this product. Both the press release and the presentation are furnished, not filed, meaning they are not automatically incorporated into other securities law filings unless specifically referenced.
Aytu BioPharma reported Q1 fiscal 2026 results showing net income from continuing operations of $1.965 million, driven by a $3.784 million non-cash gain from derivative warrant liabilities. Net revenue was $13.888 million versus $16.574 million a year ago, with the ADHD portfolio contributing $13.156 million. Gross profit was $9.186 million and loss from operations was $1.504 million as operating expenses decreased year over year.
Cash and cash equivalents were $32.630 million and total assets $124.988 million. The revolving credit facility balance was $14.873 million, and term loan debt (net) was $12.304 million. Shares outstanding were 9,911,913 as of September 30, 2025; as of November 1, 2025, common stock outstanding was 10,188,208.
The company anticipates launching EXXUA for major depressive disorder in the second fiscal quarter of 2026. During the quarter, 935,000 prefunded warrants were exercised into common stock. In June 2025, Aytu raised $16.6 million in gross proceeds via common stock and prefunded warrants to support working capital and EXXUA commercialization.
AYTU BioPharma furnished an update on its fiscal 2026 first quarter operational and financial results via a press release and scheduled a conference call and live audio webcast for November 13, 2025 at 4:30 p.m. Eastern time to discuss the results and take questions.
The webcast and telephone access details are provided in the press release, with a replay available on the company’s website and by phone at the company’s discretion. The press release is furnished as Exhibit 99.1 and is not deemed filed under the Exchange Act unless specifically incorporated by reference.
Aytu BioPharma (AYTU) set its 2026 annual meeting for December 10, 2025 at 10:00 a.m. MT in Denver. Stockholders of record at the close of business on October 13, 2025 may vote; 10,188,208 shares of common stock were outstanding and entitled to vote. A quorum requires at least one-third of eligible shares.
Stockholders will vote to elect five directors, ratify Grant Thornton as independent auditor for the fiscal year ending June 30, 2026, and approve, on a non-binding advisory basis, 2026 executive compensation. The Board recommends voting FOR all items. Four of five directors are independent under Nasdaq rules; John A. Donofrio, Jr. serves as Chairman.
Audit fees were $849,000 in fiscal 2025 versus $1,018,000 in fiscal 2024. The Board met 12 times in fiscal 2025; the Audit Committee met six times and the Compensation Committee once. Effective July 1, 2025, non-employee director compensation includes cash retainers and annual grants of 10,000 restricted shares or RSUs. In October 2025, equity awards were granted to executives, including 22,500 restricted shares to the CEO, 17,500 to the CFO, and 12,500 each to the CBO and CCO, vesting over three years.
AYTU BioPharma (AYTU) director filed a Form 5 reporting annual changes in beneficial ownership for the fiscal year ended 06/30/2025.
The filing lists 21,152 common shares held directly and 50 common shares held indirectly through Alpha Venture Capital Management, LLC. It also notes historical transactions: a purchase of 10,000 shares on 11/18/2020 and a sale of 209 shares on 12/30/2020. After the 10:1 reverse split on 12/10/2020, the 11/18/2020 purchase price equated to $9.23 per share, with $1,929.07 attributed to 209 shares, and the 12/30/2020 sale totaled $1,256.09. The filing states the reporting person did not realize any profit in connection with this short-swing purchase and sale.
The direct holdings include 10,000 restricted shares granted on 10/03/2025. A remark notes a correction to totals previously reported on a Form 4 filed on 04/16/2021.